Zeda Rosenberg is CEO of IPM, a nonprofit working to develop new HIV prevention and sexual and reproductive health products for women. Previously, she served as scientific director for the HIV Prevention Trials Network at Family Health International, and senior scientist at the U.S. National Institute of Allergy and Infectious Diseases at NIH. She received her master's in epidemiology and a doctorate in microbiology from Harvard University.
Adolescent girls and women bear a disproportionate and persistent burden of the virus. Zeda Rosenberg, CEO of the International Partnership for Microbicides, discusses the importance of scientific innovation to stop HIV infections in women.
If we translate the Sustainable Development Goals from aspirations to outcomes, young women will have a brighter future — one that is free of HIV. Fulfilling this vision depends on international commitment to making existing prevention methods available to women and supporting urgently needed research to develop new technologies that would help women protect themselves and stay healthy.
Ending AIDS will not happen unless women have new options to use to keep themselves healthy and safe, International Partnership for Microbicides CEO Zeda F. Rosenberg and Microbicide Trials Network Principal Investigator Sharon Hillier argue in this exclusive commentary.
It’ll perhaps take a decade or more to come up with an HIV vaccine. So we need to look at other options and continued investments in other novel prevention technologies, says Zeda Rosenberg, CEO of the International Partnership for Microbicides in an exclusive editorial for World AIDS Day.